Alembic Pharmaceuticals Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "Alembic Pharmaceuticals Limited receives USFDA Final Approval for Loteprednol Etabonate and Tobramycin Ophthalmic Suspension, 0.5%/0.3%".
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has received final approval from the USFDA (US Food and Drug Administration) for its Loteprednol Etabonate and Tobramycin Ophthalmic Suspension in the 0.5%/0.3% strength. This is an eye-care product used to treat inflammation and bacterial infection in the eye. With this approval, Alembic can now manufacture and sell this formulation in the United States, adding another product to its US portfolio. The company already has a strong presence in the US generic market, and this approval adds to its ophthalmology segment offerings.
This approval strengthens Alembic's US generics business and opens up a new revenue stream from the US market. It is positive for shareholders as it expands the company's product basket in a key export geography, though individual product contributions are typically modest.